eligibility_summary
Inclusion: Adults ≥18, newly diagnosed, untreated, histology‑confirmed DLBCL, ≥1 measurable FDG‑PET+ lesion (>1.5 cm LN), stage II–IV, ECOG 0–2, life ≥3 mo, adequate hematology, liver, renal, coagulation (with marrow/liver adjustments), negative pregnancy test + contraception, consent. Exclusion: Special DLBCL subtypes or transformed disease, CNS involvement, prior HSCT/therapy (except brief steroids), recent anticancer herbal meds, allergy, other trials, active infections (HIV/HBV/HCV/syphilis), adherence issues or ILD, major CV disease/QTc>450/LVEF<50/uncontrolled HTN, other cancer <2 yrs, pregnant/breastfeeding, investigator decision.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: Phase I/II single-arm R-CMOP for newly diagnosed DLBCL. Drugs and mechanisms (type): • Rituximab (chimeric anti-CD20 monoclonal antibody): binds CD20 on B cells, induces complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and apoptosis. • Cyclophosphamide (alkylating agent): DNA crosslinking → cytotoxicity. • Mitoxantrone hydrochloride liposome (liposomal anthracenedione, topoisomerase II inhibitor): DNA intercalation and topo II inhibition, liposomal delivery to enhance tumor exposure. • Vincristine (vinca alkaloid): inhibits microtubule polymerization → mitotic arrest. • Prednisolone (corticosteroid): glucocorticoid receptor–mediated apoptosis of lymphoid cells. Targets: CD20+ malignant B cells, DNA replication/repair (alkylation, topo II), microtubule dynamics, immune effector pathways (CDC/ADCC), glucocorticoid signaling.